| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Chief Executive Officer | Director +2 more
6 companies
Tang Kevin is a Chief Executive Officer at Aurinia Pharmaceuticals Inc. with holdings across 6 companies. Recent SEC Form 4 filings include 36 buys and 0 sells.
Estimated insider holdings value: $238.1M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 4,863 | $2.44 | $11,865.72 | - | - | - | |
| Jul 17, 2026 | FULC Fulcrum Therapeutics, Inc. | 10% Owner | Buy | 167,616 | $3.55 | $594,675.16 | +1.2% | - | - | |
| Jul 16, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 63,969 | $2.43 | $155,645.58 | +0.8% | - | - | |
| Jul 15, 2026 | FULC Fulcrum Therapeutics, Inc. | 10% Owner | Buy | 249,946 | $3.57 | $891,067.48 | +0.9% | - | - | |
| Jul 13, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 91,585 | $2.42 | $222,069.79 | +1.1% | - | - | |
| Jul 8, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 57,210 | $2.48 | $141,864.66 | +0.7% | - | - | |
| Jul 2, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 107,463 | $2.50 | $268,880.37 | +1.0% | - | - | |
| Jun 29, 2026 | BOLD Boundless Bio, Inc. | 10% Owner | Buy | 286,333 | $2.50 | $714,768.12 | +2.0% | - | - | |
| Jun 2, 2026 | AUPH Aurinia Pharmaceuticals Inc. | Chief Executive Officer | Buy | 814,606 | $15.29 | $12,455,227.01 | +1.3% | - | - | |
| Aug 5, 2025 | AUPH Aurinia Pharmaceuticals Inc. | Director | Buy | 1,300,000 | $10.45 | $13,590,000.00 | +4.0% | +12.6% | +27.2% |